Just bought a few of these this morning. David Evans has a good track record.


HIO floated on AIM at 10p in April, raising £4million in the process. Chairman Evans said he would use the cash to acquire companies in the life sciences space.

Broker and shareholder Killik suggests that any acquired business is likely to be in the field of in-vitro diagnostics, given Evans’ background and contacts within the industry.


At the time of HIO’s flotation Evans was granted options over 4.05million shares (10 per cent of the equity), which will only vest in the event that an acquisition is completed within 12 months from admission, and if the share price is in excess of 20p per share.


Once vested, the exercise period of the options will be 10 years and the exercise price will be 10p per share. Evans has a big City fan club and it is easy to see why. The companies under his stewardship have a strong record of value generation for shareholders.


He was chief executive of Shield Diagnostics prior to the merger with Axis Biochemicals to form Axis Shield in 1999. He was also chairman of Immunodiagnostic Systems, which floated in December 2004 at 51p and was trading at 1046p at the time he left the company in September 2011.

I suppose some of the people who bought in at the original float price of 10p in April might be happy to cash in on their profit, but I'm happy to wait this one out, even if it takes 7 years for David Evans to put in a similar performance to the one when he was chairman of Immundiagnostic Systems !

Admitted to AIM on 10th April so the clock is ticking now and not long left until the six months is up.


"The Board, through its extensive network of contacts, has identified a number of potentially interesting investment opportunities, although formal discussions in respect of any of these opportunities have not yet commenced. The Board anticipates the first acquisition will be a reverse takeover, in accordance with the AIM Rules for Companies, will be subject to prior shareholder approval and the publication of an admission Document and is expected to be made within 6 months of Admission. In addition, the Board may also consider making other smaller acquisitions or investments although the Directors do not intend to create a portfolio of unconnected companies."

Moving further ahead

MM size is 25K

was 2 MMs at bid 13p and 1 at offer 14.50p earlier

only 2.5K at 14.50p were quoting earlier online

A reasonable buy over the asking price after the close, something is beginning to move here now following the August retracement in the share price on very little volume.

Continuing with the recent movement up +0.625p after the large retracement.

12.50p +0.25p
second day on the rise after the last retracement, good volume yesterday

Result of GM
RNS
RNS Number : 4634W
Healthcare Investment Opportunities
27 December 2013

Result of General Meeting



Healthcare Investment Opportunities Plc

(the "Company")



Healthcare Investment Opportunities plc (AIM: HIO), an investment company focusing on the healthcare sector, announces that at its General Meeting held earlier today all resolutions, as announced by the Company on 10 December 2013, were duly passed. The Company will commence dealings under its new name of Collagen Solutions plc on 2nd January 2014.

Director Shareholding
RNS
RNS Number : 4668W
Healthcare Investment Opportunities
27 December 2013



27 December 2013



Healthcare Investment Opportunities Plc

(the "Company")



Director Shareholding



Healthcare Investment Opportunities plc (AIM: HIO), an investment company focusing on the healthcare sector, announces that today Malcolm Gillies, a Director of Healthcare Investment Opportunities, has purchased a total of 250,000 ordinary shares at an average price of 12.789 pence per share.



This brings Malcolm Gillies' interest in the Company's current issued share capital to 500,000 being 1.24% of the current issued share capital.

This company has now changed its name to Collagen Solutions.